ABL Bio Immuno-oncology Bispecific Antibody 'ABL501' Obtains Patent in Japan
[Asia Economy Reporter Chunhee Lee] Bispecific antibody specialist ABL Bio announced on the 14th that it has completed the registration of a Japanese patent for its immuno-oncology bispecific antibody 'ABL501.' Accordingly, ABL Bio will secure rights within Japan for ABL501 and its uses until 2039.
ABL501 is a bispecific antibody candidate developed to overcome the low response rate and resistance, which are limitations of existing PD-(L)1 immunotherapies. It applies ABL Bio's immunomodulator-based bispecific antibody platform ‘Grabody-I.’ Through this, it targets two different immune checkpoint proteins, PD-L1 and LAG-3. ABL501 blocks the binding of LAG-3 to MHCII and PD-L1 to PD-1, preventing T cell inactivation caused by tumors. Currently, a Phase 1 clinical trial is underway in South Korea.
LAG-3 has gained attention since March when multinational pharmaceutical company Bristol-Myers Squibb (BMS) received approval from the U.S. Food and Drug Administration (FDA) for the LAG-3 class immuno-oncology drug ‘Opdualag’ (active ingredient relatlimab) as a treatment for melanoma. In addition, MSD (Merck & Co., USA), Novartis, and Boehringer Ingelheim are also developing next-generation LAG-3 immuno-oncology drugs.
ABL Bio filed an international patent application for ABL501 on August 21, 2019. Besides Japan, where registration has now been completed, patent examinations are ongoing in the United States, Europe, Australia, Canada, Brazil, and other regions.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Lee Sang-hoon, CEO of ABL Bio, said, “Following the registration of the Japanese patent for the B7-H3 monospecific antibody, we are pleased to announce the registration of the Japanese patent for ABL501 as well. Since patent application and registration are key strategies to secure global competitiveness, we will continue to do our best to protect global intellectual property rights.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
